landiolol has been researched along with Inflammation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, M; Baba, H; Goto, Y; Ogawa, S; Okawa, Y | 1 |
| Hagiwara, S; Iwasaka, H; Maeda, H; Noguchi, T | 1 |
1 trial(s) available for landiolol and Inflammation
| Article | Year |
|---|---|
Perioperative use of a beta blocker in coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Creatine Kinase, MB Form; Disease-Free Survival; Drug Administration Schedule; Humans; Incidence; Inflammation; Infusions, Parenteral; Japan; Male; Middle Aged; Morpholines; Prospective Studies; Time Factors; Treatment Outcome; Troponin I; Urea | 2013 |
1 other study(ies) available for landiolol and Inflammation
| Article | Year |
|---|---|
Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Blotting, Western; Disease Models, Animal; Heart Rate; Hemodynamics; HMGB1 Protein; Immunohistochemistry; Inflammation; Interleukin-6; Lipopolysaccharides; Lung; Male; Morpholines; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Urea | 2009 |